Autism Spectrum Disorder Trial, Recruiting NCT06227780 Sponsor: Children's Hospital Medical Center, Cincinnati Condition: Autism Spectrum Disorder
Back to Autism Spectrum Disorder

Autism Spectrum Disorder Trial, Recruiting

NCT06227780
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The trial has three separate groups. People may be considered for one of the following:

Fragile X Syndrome (FXS) Group:

  • Children between 5 and 10 years old (inclusive)
  • Children who have had a genetic test confirming a full FMR1 gene mutation (the genetic change that causes Fragile X Syndrome)

Autism Spectrum Disorder (ASD) Group:

  • Children between 5 and 10 years old (inclusive)
  • Children with no known genetic mutation
  • Children who have a formal documented diagnosis of ASD
  • Children who score 15 or below on a specific screening questionnaire called the SCQ (confirm with trial site)
  • Children who the trial doctor considers to be in good general health

Typical Development Control (TDC) Group:

  • Children between 5 and 10 years old (inclusive)
  • Children with no known genetic mutation
  • Children who have a formal documented diagnosis of ASD
  • Children who score 8 or below on the SCQ screening questionnaire
  • Children who the trial doctor considers to be in good general health
  • Children who have reached normal developmental milestones
  • Children with no family history of inherited neurological or psychiatric conditions
  • Children who score above 85 on a cognitive assessment called the Stanford-Binet IQ test

Who may not be able to join:

  • Children who have hearing or vision problems that cannot be fully corrected with aids or glasses
  • Children who have had a history of alcohol or drug misuse or dependence within the past 6 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ernest V Pedapati, MD, Children's Hospital Medical Center, Cincinnati

Phone: 513-636-0875

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
24 May 2023
Est. completion
24 May 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Alpha auditory entrainment versus sham effect on Word Learning Index during the Statistical Learning Passive Task.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov